Share Price, page-8584

I hope we do the PhIII trials of 2591 for Phelan McDermid syndrome on our own - across multiple sites both in the USA, and here in Australia as well, in collaboration with both the FDA and our TGA. Would that be stretching us too much? I reckon it would be a better investment of our $200m cash rather than leaving it in the bank. Even if it took us longer than a bigger partner could achieve, and cost us more than we expect, it would be a great learning exercise that we could build upon for more trials in the future. We as shareholders would just have to be patient with our top management team. Alternatively - could we partner with Acadia to assist us to conduct PhIII trials in some way, so we gain some experience in going that far, but with Acadia, which has experience in this area, to work alongside us.